Johnson & Johnson's Icotrokinra Plans Head-to-Head Trial Against Ustekinumab

Johnson & Johnson's icotrokinra, a first-in-class oral peptide targeting the IL-23 receptor, has shown promising results in treating moderate to severe plaque psoriasis, as reported in the phase 3 ICONIC-LEAD trial presented at the 2025 American Academy of Dermatology meeting. The trial indicated that nearly 65% of patients achieved clear or almost clear skin after 16 weeks, with improvements continuing to 74% by week 24. Following these results, Johnson & Johnson announced plans for the ICONIC-ASCEND trial, aiming to compare icotrokinra directly with the injectable biologic ustekinumab. Principal investigator Robert Bissonnette highlighted the potential of icotrokinra to provide a favorable balance of efficacy and safety in a once-daily pill format. Adverse events were similar in both the icotrokinra and placebo groups, indicating a favorable safety profile. The trial's findings may significantly enhance treatment options for individuals suffering from this chronic skin condition.